Biobanking of derivatives from radical retropubic and robot-assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network

Prostate

Volumn 74, Issue 1, 2014, Pages 61-69

  Darshan, Medha ^a   Zheng, Qizhi ^a   Fedor, Helen L ^a   Wyhs, Nicolas ^a   Yegnasubramanian, Srinivasan ^a   Lee, Peng ^b   Melamed, Jonathan ^b   Netto, George J ^a   Trock, Bruce J ^a   De Marzo, Angelo M ^a   Sfanos, Karen S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biobanking; biomarker; biorepository; DNA; prostate cancer; RNA

Indexed keywords

HEPSIN; MICRORNA; MICRORNA 141; MICRORNA 221; MICRORNA 26A; MICRORNA 26B; RACEMASE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RESEARCH; DNA EXTRACTION; GENE EXPRESSION; GENE FUSION; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY CONTROL; RADICAL RETROPUBIC PROSTATECTOMY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; ROBOT ASSISTED LAPAROSCOPIC PROSTATECTOMY; SPECTROPHOTOMETRY;

BIOBANKING; BIOMARKER; BIOREPOSITORY; DNA; PROSTATE CANCER; RNA;

AGED; HUMANS; LAPAROSCOPY; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; ROBOTICS; TISSUE BANKS;

EID: 84890115054     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22730     Document Type: Article

References (30)

1. Vaught JB,. Biorepository and biospecimen science: A new focus for CEBP. Cancer Epidemiol Biomarkers Prev 2006; 15 (9): 1572-1573.
2. Esgueva R, Park K, Kim R, Kitabayashi N, Barbieri CE, Dorsey PJJ, Abraham C, Banerjee S, Leung RA, Tewari AK, Terry S, Shevchuk MM, Rickman DS, Rubin MA,. Next-generation prostate cancer biobanking: Toward a processing protocol amenable for the International Cancer Genome Consortium. Diagn Mol Pathol 2012; 21 (2): 61-68. 10.1097/PDM. 1090b1013e31823b31826da31826.
3. Kerger M, Hong M, Pedersen J, Nottle T, Ryan A, Mills J, Peters J, Moon D, Crowe H, Costello A, Corcoran N, Hovens C,. Microscopic assessment of fresh prostate tumour specimens yields significantly increased rates of correctly annotated samples for downstream analysis. Pathology 2012; 44 (3): 204-208.
4. Carmignani L, Picozzi S, Casellato S, Bozzini G, Marenghi C, Macchi A, Lunelli L, Rubino B, Clemente C,. A proposed new technique in prostate cancer tissue bio-banking: Our experience with a new protocol. Pathol Oncol Res 2012; 18 (3): 663-668.
5. Brimo F, Sircar K, Chevalier S, Saad F, Lacombe L, Têtu B, Scarlata E, Aprikian A,. Banking of fresh-frozen prostate tissue using the alternate mirror image protocol: Methods, validation, and impact on the pathological prognostic parameters in radical prostatectomy. Cell Tissue Bank 2012; 13 (4): 631-638.
6. Ricciardelli C, Bianco-Miotto T, Jindal S, Dodd TJ, Cohen PA, Marshall VR, Sutherland PD, Samaratunga H, Kench JG, Dong Y, Wang H, Clements JA, Risbridger GP, Sutherland RL, Tilley WD, Horsfall DJ,. Comparative biomarker expression and RNA integrity in biospecimens derived from radical retropubic and robot-assisted laparoscopic prostatectomies. Cancer Epidemiol Biomarkers Prev 2010; 19 (7): 1755-1765.
7. Steinberg AP, Gill IS,. Laparoscopic prostatectomy: A promising option in the treatment of prostate cancer. Cleve Clin J Med 2004; 71 (2): 113-114.
8. Lotan Y, Bolenz C, Gupta A, Hotze T, Ho R, Cadeddu JA, Roehrborn CG,. The effect of the approach to radical prostatectomy on the profitability of hospitals and surgeons. BJU Int 2010; 105 (11): 1531-1535.
9. Barry MJ, Gallagher PM, Skinner JS, Fowler FJ,. Adverse effects of robotic-assisted laparoscopic versus open retropubic radical prostatectomy among a nationwide random sample of medicare-age men. J Clin Oncol 2012; 30 (5): 513-518.
10. Best S, Sawers Y, Fu VX, Almassi N, Huang W, Jarrard DF,. Integrity of prostatic tissue for molecular analysis after robotic-assisted laparoscopic and open prostatectomy. Urology 2007; 70 (2): 328-332.
11. Dev H, Rickman D, Sooriakumaran P, Srivastava A, Grover S, Leung R, Kim R, Kitabayashi N, Esqueva R, Park K, Padilla J, Rubin M, Tewari A,. Biobanking after robotic-assisted radical prostatectomy: A quality assessment of providing prostate tissue for RNA studies. J Transl Med 2011; 9 (1): 121.
12. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, Trent JM, Isaacs WB, De Marzo AM,. Alpha-methylacyl-CoA racemase: A new molecular marker for prostate cancer. Cancer Res 2002; 62 (8): 2220-2226.
13. Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Watson MA, Milbrandt J,. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 2001; 61 (15): 5692-5696.
14. Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C, Chen Y, Nau M, Ravindranath L, Chen Y, Dobi A, Srikantan V, Sesterhenn IA, McLeod DG, Vahey M, Moul JW, Srivastava S,. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005; 24 (23): 3847-3852.
15. Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM,. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget 2011; 2 (9)
16. Sørensen KD, Ørntoft TF,. Discovery of prostate cancer biomarkers by microarray gene expression profiling. Expert Rev Mol Diagn 2009; 10 (1): 49-64.
17. Waltering KK, Porkka KP, Jalava SE, Urbanucci A, Kohonen PJ, Latonen LM, Kallioniemi OP, Jenster G, Visakorpi T,. Androgen regulation of micro-RNAs in prostate cancer. Prostate 2011; 71 (6): 604-614.
18. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM,. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310 (5748): 644-648.
19. Samaratunga H, Montironi R, True L, Epstein JI, Griffiths DF, Humphrey PA, van der Kwast T, Wheeler TM, Srigley JR, Delahunt B, Egevad L,. International society of urological pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. Working group 1: Specimen handling. Mod Pathol 2011; 24 (1): 6-15.
20. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TLJ, Visakorpi T,. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67 (13): 6130-6135.
21. Selth LA, Townley S, Gillis JL, Ochnik AM, Murti K, Macfarlane RJ, Chi KN, Marshall VR, Tilley WD, Butler LM,. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer 2012; 131 (3): 652-661.
22. Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, Beissbarth T, Kuner R, Sültmann H,. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2011; 128 (3): 608-616.
23. Yaman Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N, Gezer U,. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumor Biol 2011; 32 (3): 583-588.
24. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M,. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105 (30): 10513-10518.
25. Zhang H-L, Qin X-J, Cao D-L, Zhu Y, Yao X-D, Zhang S-L, Dai B, Ye D-W,. An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions. Asian J Androl 2013; 15 (2): 231-235.
26. Bryant RJ, Pawlowski T, Catto JWF, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T, Hamdy FC,. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012; 106 (4): 768-774.
27. Gonzales JC, Fink LM, Goodman OB Jr, Symanowski JT, Vogelzang NJ, Ward DC,. Comparison of circulating microRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer 2011; 9 (1): 39-45.
28. Nguyen HCN, Xie W, Yang M, Hsieh C-L, Drouin S, Lee G-SM, Kantoff PW,. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 2013; 73 (4): 346-354.
29. Dash A, Maine IP, Varambally S, Shen R, Chinnaiyan AM, Rubin MA,. Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. Am J Pathol 2002; 161 (5): 1743-1748.
30. Li J, Zhang Z-H, Yin C-J, Pavlovich C, Luo J, Getzenberg R, Zhang W,. Effect of surgical procedures on prostate tumor gene expression profiles. Asian J Androl 2012; 14 (5): 708-714.